IP Library Granted Patent US 8,784,817
Granted Patent B2
US 8,784,817 · App. 13/767,292 · Granted Jul 22, 2014

Method for killing IL-1 alpha expressing cells

Inventor: John Simard (Austin, TX)
Assignee: XBiotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,817
App. No.
13/767,292
Granted
Jul 22, 2014
Kind
B2
Abstract

Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.

Claims (2)

1. A method of killing a human cell expressing human interleukin-1alpha (IL-1α), the method comprising the step of contacting the cell with a purified human IgG1 monoclonal antibody (mAb) that specifically binds to human IL-1α, wherein the mAb comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 11, and is conjugated to a cytotoxin.

2. The method of claim 1 , wherein the human cell is a cancer cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2020
From: XBIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 051769/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2013
From: SIMARD, JOHN
To: XBIOTECH, INC.
Reel/Frame 029816/0158 →
Continuity (6)
Continuation 13224913 · Sep 2, 2011
Division 12455458 · Jun 1, 2009
Provisional Application 61057586 · May 30, 2008
Provisional Application 61121391 · Dec 10, 2008
Provisional Application 61178350 · May 14, 2009
Related Publication 20130177982A1 · Jul 11, 2013